PMID- 36614270
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 1
DP  - 2023 Jan 3
TI  - Type 2 Diabetes in Obesity: A Systems Biology Study on Serum and Adipose Tissue 
      Proteomic Profiles.
LID - 10.3390/ijms24010827 [doi]
LID - 827
AB  - Obesity is associated with metabolic disorders such as insulin resistance and 
      type 2 diabetes mellitus (T2DM), further increasing an already heightened 
      cardiovascular risk. Here, amongst obese class III bariatric surgery patients, we 
      have investigated the effect of T2DM in serum and in two, same patient, adipose 
      tissue (AT) depots through proteomic profile expression analyses. Serum and AT 
      samples from subcutaneous (SAT) and visceral (VAT) fat were collected during 
      bariatric surgery. Bead-based targeted multiplex assay systems were used to 
      simultaneously detect and quantify multiple targets in serum samples (targeted 
      proteomics) and analyze changes in adipokine serum composition. AT samples were 
      assessed through an untargeted proteomics approach. Through a systems biology 
      analysis of the proteomic data, information on the affected biological pathways 
      was acquired. In obese class III individuals, the presence of T2DM induced a 
      significantly higher systemic release of ghrelin, GLP-1, glucagon, MMP3, BAFF, 
      chitinase 3-like 1, TNF-R1 and TNF-R2, and a lower systemic release of IL-8. SAT 
      and VAT proteomes belonging to the same patient showed significant differences in 
      local protein content. While the proteins upregulated in VAT were indicative of 
      metabolic dysregulation, SAT protein upregulation suggested adequate endocrine 
      regulation. The presence of T2DM significantly affected VAT protein composition 
      through the upregulation of dysregulating metabolic pathways, but SAT protein 
      composition was not significantly modified. Our results show that T2DM induces 
      metabolic dysregulation in obese individuals with changes in systemic marker 
      levels and impairment of proteostasis in VAT but not in SAT.
FAU - Arderiu, Gemma
AU  - Arderiu G
AD  - Cardiovascular-Program, Institut d'Investigacio Biomedica Sant Pau (IIB Sant 
      Pau), 08041 Barcelona, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares 
      (CiberCV), 28029 Barcelona, Spain.
FAU - Mendieta, Guiomar
AU  - Mendieta G
AD  - Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
FAU - Gallinat, Alex
AU  - Gallinat A
AUID- ORCID: 0000-0002-1521-2175
AD  - Cardiovascular-Program, Institut d'Investigacio Biomedica Sant Pau (IIB Sant 
      Pau), 08041 Barcelona, Spain.
FAU - Lambert, Carmen
AU  - Lambert C
AUID- ORCID: 0000-0002-7929-4990
AD  - Cardiovascular-Program, Institut d'Investigacio Biomedica Sant Pau (IIB Sant 
      Pau), 08041 Barcelona, Spain.
AD  - IPSA-Instituto de Investigacion Sanitaria del Principado de Asturias, 33011 
      Oviedo, Spain.
FAU - Diez-Caballero, Alberto
AU  - Diez-Caballero A
AD  - Centro Medico Teknon, Grupo Quiron Salut, 08022 Barcelona, Spain.
FAU - Ballesta, Carlos
AU  - Ballesta C
AD  - Centro Medico Teknon, Grupo Quiron Salut, 08022 Barcelona, Spain.
FAU - Badimon, Lina
AU  - Badimon L
AUID- ORCID: 0000-0002-9162-2459
AD  - Cardiovascular-Program, Institut d'Investigacio Biomedica Sant Pau (IIB Sant 
      Pau), 08041 Barcelona, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares 
      (CiberCV), 28029 Barcelona, Spain.
LA  - eng
GR  - PID2019-107160RB-100/Plan National Proyectos Investigacion y Desarrollo/
GR  - CIBERCV-CB16/11/00411/Centro de Investigacion Biomedica en Red Cardiovascular/
GR  - PI20/01517/Institute of Health Carlos III (ISCIII)/
GR  - 2017 SGR 1480/Secretaria d'Universitats i Recerca, Departament d'Economia i 
      Coneixement/
PT  - Journal Article
DEP - 20230103
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Subcutaneous Fat/metabolism
MH  - Proteomics
MH  - Systems Biology
MH  - Obesity/metabolism
MH  - Adipose Tissue/metabolism
MH  - Intra-Abdominal Fat/metabolism
PMC - PMC9821208
OTO - NOTNLM
OT  - diabetes
OT  - proteomic analysis
OT  - subcutaneous adipose tissue
OT  - visceral adipose tissue
COIS- L.B. declares to have acted as a SAB member of Sanofi, Ionnis, Pfizer and 
      NovoNordisk; to have a Research Grant from AstraZeneca; to have received speaker 
      fees from Sanofi and Bayer and to have founded the Spin-offs Glycardial 
      Diagnostics SL and Ivastatin Therapeutics S (all unrelated to this work). The 
      remaining authors have nothing to disclose. The authors declare no conflict of 
      interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/01/03
CRDT- 2023/01/08 01:26
PHST- 2022/11/22 00:00 [received]
PHST- 2022/12/16 00:00 [revised]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/01/08 01:26 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2023/01/03 00:00 [pmc-release]
AID - ijms24010827 [pii]
AID - ijms-24-00827 [pii]
AID - 10.3390/ijms24010827 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jan 3;24(1):827. doi: 10.3390/ijms24010827.